Via Vaccine News Daily :
" Doctors are reporting that an outbreak of cholera in Somalia’s war-torn capital has killed more than 20 people.
Dr. Lul Mohamed recently said that Banadir maternity hospital in Mogadishu has been inundated with more than 150 cases of the diarrheal disease. She said the hospital is low on supplies as well as the cash needed to pay the hospital’s workers, according to the AP."
Showing posts with label Vaccine News Daily. Show all posts
Showing posts with label Vaccine News Daily. Show all posts
Tuesday, March 15, 2011
Tuesday, March 8, 2011
Brazil facing second largest dengue outbreak in its history
Via Vaccine News Daily :
" The Brazilian state of Amazonas has reported 15,548 cases of dengue as of last week, ranking it only behind the 19,000 cases registered during a 2001 epidemic.
While the first dengue outbreak in 1998 only had dengue type 1 and the second outbreak in 2001 had both types 1 and 2, the current outbreak has a higher risk than the others because it includes all four types of dengue, Inside Costa Rica reports.This epidemic has seen nine deaths as of March 1, all from dengue types 1 and 2.
Two of the dead were minors while the other seven came from the young and adult groups, according to Inside Costa Rica. Four other deaths are currently being investigated to determine if dengue was the cause."
" The Brazilian state of Amazonas has reported 15,548 cases of dengue as of last week, ranking it only behind the 19,000 cases registered during a 2001 epidemic.
While the first dengue outbreak in 1998 only had dengue type 1 and the second outbreak in 2001 had both types 1 and 2, the current outbreak has a higher risk than the others because it includes all four types of dengue, Inside Costa Rica reports.This epidemic has seen nine deaths as of March 1, all from dengue types 1 and 2.
Two of the dead were minors while the other seven came from the young and adult groups, according to Inside Costa Rica. Four other deaths are currently being investigated to determine if dengue was the cause."
Thursday, July 8, 2010
Failure of trial of H5N1 influenza patch revealed
Via Vaccine News Daily :
" The reason for the failure of a Phase II clinical trial of Intercell AG's Vaccine Enhancement Patch for H5N1 influenza could be a faulty hemagglutinin inhibition assay, a newly released report reveals.
The patch is administered alongside a single vaccine shot and is meant to support dose-sparing efforts should an influenza pandemic arise, BioWorld.com reports.The Phase II clinical trial was conducted under a $128 million contract with the U.S. Department of Health and Human Services.
Two different doses of H5N1 influenza vaccine were tested in 500 subjects. No difference was found in seroprotection rates between those who had received both the vaccine as well as the VEP and those who only received the vaccine."
" The reason for the failure of a Phase II clinical trial of Intercell AG's Vaccine Enhancement Patch for H5N1 influenza could be a faulty hemagglutinin inhibition assay, a newly released report reveals.
The patch is administered alongside a single vaccine shot and is meant to support dose-sparing efforts should an influenza pandemic arise, BioWorld.com reports.The Phase II clinical trial was conducted under a $128 million contract with the U.S. Department of Health and Human Services.
Two different doses of H5N1 influenza vaccine were tested in 500 subjects. No difference was found in seroprotection rates between those who had received both the vaccine as well as the VEP and those who only received the vaccine."
Thursday, May 27, 2010
Hawaii : Preclinical development of dengue vaccine announced
From Vaccine News Daily, a glimmer of hope? :
" Advanced BioScience Laboratories, Inc., and Hawaii Biotech, Inc., announced on May 25 that they will be joining forces with the National Institute of Allergy and Infectious Diseases for preclinical development of a dengue vaccine.
Officials with Hawaii Biotech said that they plan to begin the first phase of a human clinical study with its tetravalent dengue vaccine candidate later this year.
The sub-unit vaccine will be designed with high resistance to all four of the native viral antigens, which officials believe will provide balanced immunity.
Advanced BioScience, through a contract from the National Institute of Allergy and Infectious Diseases, will oversee the manufacturing and testing of all supplies.
“In preparing to evaluate our tetravalent dengue vaccine in the clinic, we looked for a contract research organization with deep experience in viral vaccine development,” Elliot Parks, Hawaii Biotech's president and CEO, said."
" Advanced BioScience Laboratories, Inc., and Hawaii Biotech, Inc., announced on May 25 that they will be joining forces with the National Institute of Allergy and Infectious Diseases for preclinical development of a dengue vaccine.
Officials with Hawaii Biotech said that they plan to begin the first phase of a human clinical study with its tetravalent dengue vaccine candidate later this year.
The sub-unit vaccine will be designed with high resistance to all four of the native viral antigens, which officials believe will provide balanced immunity.
Advanced BioScience, through a contract from the National Institute of Allergy and Infectious Diseases, will oversee the manufacturing and testing of all supplies.
“In preparing to evaluate our tetravalent dengue vaccine in the clinic, we looked for a contract research organization with deep experience in viral vaccine development,” Elliot Parks, Hawaii Biotech's president and CEO, said."
Subscribe to:
Posts (Atom)